

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): An apheresis device comprising a solid carrier capable of being contacted with the blood or plasma flow, characterized in that the solid carrier includes an amyloid- β -precursor-protein(APP)-binding receptor.

Claim 2 (Original): A device according to claim 1, characterized in that the APP-binding receptor is selected from anti-APP antibodies, anti-A β_{40} antibodies, anti-A β_{42} antibodies, APP-binding proteins, in particular gelsolin, apoJ or apoE, APP-binding peptides, APP-binding gangliosides, in particular GM1, or APP-binding nucleic acids, in particular aptamers, or mixtures of these receptors.

Claim 3 (Currently Amended): A device according to claim 1 [[or 2]], characterized in that the carrier is a sterile and pyrogen-free column.

Claim 4 (Currently Amended): A method of using the ~~The use of a~~ device according to ~~any one of claims 1 to 3~~ claim 1, for providing a treatment of Alzheimer's Disease or for prevention of the latter.